- Home
- MULN vs INAB Comparison
MULN vs INAB Comparison
Compare MULN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- INAB
- Stock Information
- Founded
- MULN 2014
- INAB 2016
- Country
- MULN United States
- INAB United States
- Employees
- MULN N/A
- INAB N/A
- Industry
- MULN Auto Manufacturing
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- MULN Consumer Discretionary
- INAB Health Care
- Exchange
- MULN Nasdaq
- INAB Nasdaq
- Market Cap
- MULN 15.1M
- INAB 24.0M
- IPO Year
- MULN N/A
- INAB 2021
- Fundamental
- Price
- MULN $1.19
- INAB $0.25
- Analyst Decision
- MULN
- INAB Strong Buy
- Analyst Count
- MULN 0
- INAB 3
- Target Price
- MULN N/A
- INAB $7.75
- AVG Volume (30 Days)
- MULN 2.1M
- INAB 748.9K
- Earning Date
- MULN 02-11-2025
- INAB 11-12-2024
- Dividend Yield
- MULN N/A
- INAB N/A
- EPS Growth
- MULN N/A
- INAB N/A
- EPS
- MULN N/A
- INAB N/A
- Revenue
- MULN $156,570.00
- INAB N/A
- Revenue This Year
- MULN N/A
- INAB N/A
- Revenue Next Year
- MULN N/A
- INAB N/A
- P/E Ratio
- MULN N/A
- INAB N/A
- Revenue Growth
- MULN N/A
- INAB N/A
- 52 Week Low
- MULN $1.14
- INAB $0.22
- 52 Week High
- MULN $1,799.00
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- MULN 27.94
- INAB 39.26
- Support Level
- MULN $2.11
- INAB $0.28
- Resistance Level
- MULN $1.57
- INAB $0.32
- Average True Range (ATR)
- MULN 0.22
- INAB 0.03
- MACD
- MULN -0.01
- INAB -0.01
- Stochastic Oscillator
- MULN 3.55
- INAB 13.73
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and energy solutions. The company strives to make electric vehicles more accessible by building an end-to-end ecosystem that takes care of all aspects of electric vehicle ownership. The Company owns and partners with several synergistic businesses, all working towards the same goal of creating clean and scalable electric vehicles and energy solutions. The company has two segments Bollinger and Mullen/ELMS, which generates revenue.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.